BioVie Chief Medical Officer Dr Joseph Palumbo joined Steve Darling from Proactive to share some thoughts on the recent encouraging news from the company that NE3107 had an impact on improving patients’ DNA methylation profiles, potentially impacting biomarkers of aging-related disease states like Alzheimer’s. Palumbo also talked about another interesting announcement that Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score which is considered to be very meaningful by Parkinson’s experts.
BioVie recent announcements around Alzheimers and Parkinson's shows encouraging data
